Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in a phase 3 trial in early breast cancer. More: AstraZeneca, Daiichi Sankyo's
read more
UCB’s developmental treatment may be eligible for patient access More: MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d Source: News
read more
Demonstrate your skill and prowess by entering this year’s awards! More: PharmaTimes Clinical Researcher of the Year – The Americas Awards Source: News
read moreXellia Pharmaceuticals, the largest and last maker of key antibiotics APIs in Europe, will shutter its Copenhagen production facility in a move seen as a blow to EU reshoring efforts. More: Xellia to shutter Copenhagen antibiotics plant, dealing a blow
read moreAs the U.S. GLP-1 market is in a period of transition, Novo Nordisk is holding out hope for faster growth in the second half of 2025. More: Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
read moreModerna is being audited by the PMCPA after once again being found to have brought discredit on the pharma industry, putting the company on a path that could lead to its suspension from the U.K. trade group ABPI. The latest
read more© 1994 - 2025 B.M. Pharmaceuticals